| Q57771763 | 1,3,4-Thiadiazol-2-amine Derivatives as Urotensin-II Receptor (UT) Antagonists |
| Q81106517 | 2-Aminomethyl piperidines as novel urotensin-II receptor antagonists |
| Q36894521 | A 'reverse' phylogenetic approach for identification of novel osmoregulatory and cardiovascular hormones in vertebrates |
| Q22253848 | A G protein-coupled receptor for UDP-glucose |
| Q33655911 | A Novel Urotensin II Receptor Antagonist, KR-36996 Inhibits Smooth Muscle Proliferation through ERK/ROS Pathway |
| Q64041645 | A Novel and Highly Potent Urotensin II Receptor Antagonist Inhibits Urotensin II-Induced Pressure Response in Mice |
| Q91287233 | A Pilot Study Using a Multistaged Integrated Analysis of Gene Expression and Methylation to Evaluate Mechanisms for Evening Fatigue in Women Who Received Chemotherapy for Breast Cancer |
| Q36492706 | A closer look at the role of urotensin II in the metabolic syndrome |
| Q42088044 | A comparison of assay performance between the calcium mobilization and the dynamic mass redistribution technologies for the human urotensin receptor. |
| Q39549825 | A highly sensitive quantitative cytosensor technique for the identification of receptor ligands in tissue extracts |
| Q40703439 | A new ligand for the urotensin II receptor |
| Q42139903 | A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands |
| Q48801743 | A novel hypothalamic neuroendocrine peptide: URP (urotensin-II-related peptide)? |
| Q37737587 | A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects |
| Q36782714 | A review of the genetics of essential hypertension |
| Q51525681 | A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension. |
| Q90234227 | Activation of a nerve injury transcriptional signature in airway-innervating sensory neurons after Lipopolysaccharide induced lung inflammation |
| Q37660867 | Acute Effect of Central Administration of Urotensin II on Baroreflex and Blood Pressure in Conscious Normotensive Rabbits |
| Q34238307 | Addressing those two that go together: the angiotensin II receptors and their role in blood-flow regulation |
| Q51328508 | Age-Related Reduction of Contractile Responses to Urotensin II Is Seen in Aortas from Wistar Rats but Not from Type 2 Diabetic Goto-Kakizaki Rats. |
| Q39015982 | Aging and Erectile Dysfunction |
| Q81569104 | Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout |
| Q46528121 | Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists |
| Q46449669 | Aminomethylpiperazines as selective urotensin antagonists |
| Q104734062 | An Academic Clinician's Road Map to Hypertension Genomics: Recent Advances and Future Directions MMXX |
| Q34345899 | An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans |
| Q38252981 | An atlas of G-protein coupled receptor expression and function in human subcutaneous adipose tissue |
| Q36224889 | An investigation into the expression and mechanism of action of urotensin II in chronic pressure-overloaded rat hearts |
| Q53165879 | An investigation into the origin of the biased agonism associated with the urotensin II receptor activation. |
| Q46443019 | Androgenic down-regulation of urotensin II precursor, urotensin II-related peptide precursor and androgen receptor mRNA in the mouse spinal cord |
| Q46938435 | Angiotensin II and the JNK pathway mediate urotensin II expression in response to hypoxia in rat cardiomyocytes |
| Q54368254 | Angiotensin II mediates urotensin II expression by hypoxia in cultured cardiac fibroblast. |
| Q48106723 | Another ligand fishing for G protein-coupled receptor 14. Discovery of urotensin II-related peptide in the rat brain |
| Q44016075 | Antioxidant N-acetylcysteine inhibits vasoactive agents-potentiated mitogenic effect of mildly oxidized LDL on vascular smooth muscle cells |
| Q28574681 | Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction |
| Q28478002 | Association analysis of urotensin II gene (UTS2) and flanking regions with biochemical parameters related to insulin resistance |
| Q89884928 | Association between Plasma Urotensin II and Risk of Hypertension: Findings from a Prospective Study |
| Q84136958 | Association between Thr21Met and Ser89Asn polymorphisms of the urotensin-II (UTS2) gene, diabetes mellitus, and diabetic retinopathy |
| Q93371717 | Association between vasoactive peptide urotensin II in plasma and cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a potential therapeutic target |
| Q54590701 | Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. |
| Q103837630 | Association of resistin (rs3745367) and urotensin II (rs228648 and rs2890565) gene polymorphisms with risk of type 2 diabetes mellitus in Indian population |
| Q37278556 | Association of three polymorphisms in the gene coding for endothelin-1 with essential hypertension, overweight and smoking |
| Q36320177 | Autocrine Human Urotensin II Enhances Macrophage-Derived Foam Cell Formation in Transgenic Rabbits. |
| Q46447138 | Automated synthesis of the generic peptide labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate and application to (18)F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography |
| Q28269772 | Behavioral actions of urotensin-II |
| Q42667921 | Behavioral effects of urotensin-II centrally administered in mice |
| Q51532770 | Benzo[b]thiophene-2-carboxamide derivatives as potent urotensin-II receptor antagonists. |
| Q54325417 | Biased signaling regulates the pleiotropic effects of the urotensin II receptor to modulate its cellular behaviors. |
| Q28260943 | Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes |
| Q42252347 | Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart |
| Q80590442 | Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord |
| Q104109818 | Bioinformatic analysis and functional predictions of selected regeneration-associated transcripts expressed by zebrafish microglia |
| Q37043921 | Biological properties and functional determinants of the urotensin II receptor. |
| Q80806227 | Biologically active peptides urotensin II (UII) and urotensin II-related peptide (URP), and to their cognate receptor (UT). Editorial |
| Q34240629 | Biology of the anococcygeus muscle |
| Q37235264 | Blockade of Urotensin II Receptor Prevents Vascular Dysfunction |
| Q53097030 | Blocking of urotensin receptors as new target for treatment of carrageenan induced inflammation in rats. |
| Q38310714 | Blocking the urotensin II receptor pathway ameliorates the metabolic syndrome and improves cardiac function in obese mice |
| Q43262144 | Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response |
| Q54202541 | Can early myocardial infarction-related deaths be diagnosed using postmortem urotensin receptor expression levels? |
| Q46539844 | Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade |
| Q36970805 | Cardiorenovascular effects of urotensin II and the relevance of the UT receptor. |
| Q35043105 | Cardiostimulant effects of urotensin-II in human heart in vitro |
| Q110901914 | Cardiovascular Activity |
| Q76383741 | Cardiovascular actions of human urotensin II--considerations for hypertension |
| Q28572987 | Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts |
| Q28577178 | Cardiovascular effects of urotensin II in different brain areas |
| Q35914495 | Cardiovascular role of urotensin II: effect of chronic infusion in the rat. |
| Q48709755 | Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity |
| Q34374913 | Cellular and molecular basis of portal hypertension |
| Q36597958 | Cellular and molecular biology of orphan G protein-coupled receptors |
| Q54708765 | Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat. |
| Q56987955 | Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries |
| Q37634732 | Central and Peripheral Effects of Urotensin II and Urotensin II-Related Peptides on Cardiac Baroreflex Sensitivity in Trout. |
| Q36903312 | Central and peripheral cardiovascular, ventilatory, and motor effects of trout urotensin-II in the trout |
| Q44289130 | Central cardiovascular action of urotensin II in conscious rats |
| Q44657728 | Central cardiovascular action of urotensin II in spontaneously hypertensive rats |
| Q80579308 | Central effects of native urotensin II on motor activity, ventilatory movements, and heart rate in the trout Oncorhynchus mykiss |
| Q89997241 | Cerebrovascular effects of endothelin-1 investigated using high-resolution magnetic resonance imaging in healthy volunteers |
| Q104570411 | Characterization of Four Urotensin II Receptors (UTS2Rs) in Chickens |
| Q28238520 | Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors |
| Q46186975 | Characterization of the insulinostatic effect of urotensin II: a study in the perfused rat pancreas |
| Q34204062 | Characterization of the true ortholog of the urotensin II-related peptide (URP) gene in teleosts |
| Q46424197 | Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction. |
| Q59054972 | Chemical Feature-Based Molecular Modeling of Urotensin-II Receptor Antagonists: Generation of Predictive Pharmacophore Model for Early Drug Discovery |
| Q92404225 | Chronic Urotensin-II Administration Improves Whole-Body Glucose Tolerance in High-Fat Diet-Fed Mice |
| Q46354910 | Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice |
| Q44512781 | Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy. |
| Q54704146 | Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats. |
| Q93017083 | Cilia-driven cerebrospinal fluid flow directs expression of urotensin neuropeptides to straighten the vertebrate body axis |
| Q58665243 | Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease |
| Q81644460 | Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers |
| Q38329473 | Cloning and pharmacological characterization of the cat urotensin-II receptor (UT). |
| Q42665032 | Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs |
| Q28207844 | Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues |
| Q92513248 | Commentary: Molecular pathogenesis of aortic stenosis: Will the puzzle pieces ever fit together? |
| Q35191049 | Comparative distribution and in vitro activities of the urotensin II-related peptides URP1 and URP2 in zebrafish: evidence for their colocalization in spinal cerebrospinal fluid-contacting neurons |
| Q34479147 | Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families |
| Q36609389 | Comparative understanding of UTS2 and UTS2R genes for their involvement in type 2 diabetes mellitus |
| Q74531068 | Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II |
| Q51110990 | Comparison of two competitive enzyme immunoassay kits for quantification of plasma Urotensin-II in rats. |
| Q43868528 | Concordant localization of functional urotensin II and urotensin II-related peptide binding sites in the rat brain: Atypical occurrence close to the fourth ventricle. |
| Q39038635 | Conformation and Dynamics of Human Urotensin II and Urotensin Related Peptide in Aqueous Solution. |
| Q44036542 | Congestive heart failure and expression of myocardial urotensin II. |
| Q112292074 | Conserved role of the urotensin II receptor 4 signalling pathway to control body straightness in a tetrapod |
| Q28579480 | Contractile responses of aortae from WKY and SHR to vasoconstrictors |
| Q43264408 | Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. |
| Q46981255 | Contractile responses to rat urotensin II in resting and depolarized basilar arteries. |
| Q45735762 | Daily rhythms of urotensin I and II gene expression and hormone secretion in the caudal neurosecretory system of the euryhaline flounder (Platichthys flesus). |
| Q43530127 | Deconstruction of sulfonamide inhibitors of the urotensin receptor (UT) and design and synthesis of benzylamine and benzylsulfone antagonists |
| Q42215972 | Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice |
| Q43264253 | Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats |
| Q46139106 | Deprotection of the indole (N(ind))-formyl (For) group on tryptophan employing a new reagent, N,N'-dimethylethylendiamine (DMEDA) in an aqueous solution |
| Q39812797 | Desensitisation of native and recombinant human urotensin-II receptors |
| Q58855829 | Design, Synthesis, Conformational Analysis, and Biological Studies of Urotensin-II Lactam Analogues |
| Q47408915 | Design, Synthesis, and Biological Assessment of Biased Allosteric Modulation of the Urotensin II Receptor Using Achiral 1,3,4-Benzotriazepin-2-one Turn Mimics. |
| Q46617927 | Development and pharmacological characterization of "caged" urotensin II analogs |
| Q33895713 | Development of filtration-based time-resolved fluorescence assay for the high-throughput screening of urotensin II receptor antagonist |
| Q33337625 | Development of potent and selective small-molecule human Urotensin-II antagonists |
| Q39939179 | Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction |
| Q52312977 | Diabetic macular oedema: under-represented in the genetic analysis of diabetic retinopathy. |
| Q40549079 | Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors |
| Q33199056 | Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure |
| Q80532626 | Differential levels of "urotensin-II-like" activity determined by radio-receptor and radioimmuno-assays |
| Q42059806 | Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey |
| Q42169441 | Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy |
| Q37394539 | Direct inotropic effects of exogenous and endogenous urotensin-II: divergent actions in failing and nonfailing human myocardium |
| Q28188986 | Discovery and mapping of ten novel G protein-coupled receptor genes |
| Q91295246 | Discovery of New Allosteric Modulators of the Urotensinergic System through Substitution of the Urotensin II-Related Peptide (URP) Phenylalanine Residue |
| Q34677468 | Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. |
| Q48626800 | Does cigarette smoking increase plasma urotensin II concentrations? |
| Q34260110 | Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity |
| Q33932128 | Drug discovery in the next millennium |
| Q92921145 | Dynamic Expression and Regulation of Urotensin I and Corticotropin-Releasing Hormone Receptors in Ovary of Olive Flounder Paralichthys olivaceus |
| Q46847923 | Dynamic expression pattern of corticotropin-releasing hormone, urotensin I and II genes under acute salinity and temperature challenge during early development of zebrafish |
| Q45197667 | EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. |
| Q44631771 | Effect of GABA A receptor activation on UT-coupled signaling pathways in rat cortical astrocytes |
| Q37353581 | Effect of KIOM-79 on Diabetes-Induced Myocardial Fibrosis in Zucker Diabetic Fatty Rats |
| Q28569120 | Effect of central urotensin II on heart rate, blood pressure and brain Fos immunoreactivity in conscious rats |
| Q73307200 | Effect of human urotensin-II infusion on hemodynamics and cardiac function |
| Q39760736 | Effect of urotensin II on PC12 rat pheochromocytoma cells |
| Q39018162 | Effect of urotensin II on apolipoprotein B100 and apolipoprotein A-I expression in HepG2 cell line |
| Q45274809 | Effect of urotensin II on skin microvessel tone in diabetic patients without heart failure or essential hypertension. |
| Q36800470 | Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma |
| Q41508038 | Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension |
| Q53358853 | Effects of exogenous urotensin II on vascular remodelling after balloon injury. |
| Q47700465 | Effects of hydrogen sulfide on hypoxic pulmonary vascular structural remodeling |
| Q53167895 | Effects of peripherally administered urotensin II and arginine vasotocin on the QT interval of the electrocardiogram in trout. |
| Q42275443 | Effects of urotensin II and its specific receptor antagonist urantide on rat vascular smooth muscle cells |
| Q43540403 | Effects of urotensin II in human arteries and veins of varying caliber |
| Q82711352 | Effects of urotensin II on functional activity of late endothelial progenitor cells |
| Q87759495 | Effects of urotensin II on intracellular pH regulation in cultured human internal mammary artery smooth muscle cells |
| Q33314499 | Effects of urotensin-II on cerebral blood flow and ischemia in anesthetized rats |
| Q46749370 | Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy |
| Q50593076 | Elevated expression of urotensin II and its receptor in great artery of type 2 diabetes and its significance. |
| Q46073321 | Elevated expression of urotensin II and its receptor in skeletal muscle of diabetic mouse |
| Q48010955 | Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy |
| Q28177421 | Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure |
| Q60713420 | Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy |
| Q36885668 | Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throughput screening |
| Q35033297 | Emerging roles for orphan G-protein-coupled receptors in the cardiovascular system |
| Q35909083 | Emerging roles of urotensin-II in cardiovascular disease. |
| Q37899947 | Endothelial dysfunction in the regulation of cirrhosis and portal hypertension |
| Q38989978 | Endothelial nitric oxide synthase (eNOS) (Glu298Asp) and urotensin II (UTS2 S89N) gene polymorphisms in preeclampsia: prediction and correlation with severity in Egyptian females |
| Q64446805 | Endothelins are potent vasoconstrictors, and much more besides |
| Q81781012 | Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II |
| Q33944142 | Enhanced stimulation of Akt-3/protein kinase B-gamma in human aortic smooth muscle cells |
| Q80079843 | Enhancement of vascular smooth muscle cell migration by urotensin II |
| Q50992169 | Evaluation of no-wash calcium assay kits: enabling tools for calcium mobilization. |
| Q34007711 | Evaluation of the effects of urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients |
| Q28582653 | Evidence for endogenous urotensin-II as an inhibitor of insulin secretion. Study in the perfused rat pancreas |
| Q53863403 | Evidence for the involvement of endothelin-1 but not urotensin-II in chronic lower limb ischaemia in man. |
| Q43852835 | Experimental rupture of atherosclerotic lesions increases distal vascular resistance: a limiting factor to the success of infarct angioplasty |
| Q46252944 | Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism |
| Q46312863 | Expression levels of urotensin II are associated with endoplasmic reticulum stress in patients with severe preeclampsia |
| Q48750145 | Expression of Urotensin II During Focal Cerebral Ischemic in Diabetic Rats. |
| Q40659791 | Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. |
| Q43484682 | Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure |
| Q74164190 | Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells |
| Q80388703 | Expression of urotensin-II in human coronary atherosclerosis |
| Q52565250 | Expression pattern of the orphan receptor LGR4/GPR48 gene in the mouse. |
| Q50986452 | Expressions of irisin and urotensin II and their relationships with blood pressure in patients with preeclampsia. |
| Q60713413 | Fish Peptides |
| Q36742817 | Fish caudal neurosecretory system: a model for the study of neuroendocrine secretion. |
| Q52960820 | Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium. |
| Q28257908 | From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function |
| Q28281201 | From heart to mind. The urotensin II system and its evolving neurophysiological role |
| Q35105373 | Functional Assays for Identifying Ligands at Orphan G Protein-Coupled Receptors |
| Q47830299 | Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay. |
| Q34527983 | Functional cell-based uHTS in chemical genomic drug discovery |
| Q92235064 | Functional effects of urotensin-II on intracellular pH regulators in human radial artery smooth muscle cells |
| Q34502401 | G protein-coupled receptors: dominant players in cell-cell communication |
| Q36248054 | G-protein-coupled receptor deorphanizations |
| Q83918015 | G-protein-coupled receptor microarrays for multiplexed compound screening |
| Q34233981 | GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo |
| Q74818956 | Genetic analysis of G protein-coupled receptor genes |
| Q54502525 | Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequalae in mice. |
| Q47920527 | Genetic polymorphisms of UTS2 rs2890565 Ser89Asn in cardiac hypertrophy in Chinese Han population |
| Q92645997 | Genetic polymorphisms of UTS2 rs2890565 Ser89Asn in coronary heart disease and myocardial infarction in Chinese population |
| Q28287330 | Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese |
| Q45841710 | H2 S inhibits the activation of hepatic stellate cells and downregulates the expression of urotensin II. |
| Q48592615 | Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance |
| Q46719870 | Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats |
| Q46638695 | Hemodynamic-independent anti-natriuretic effect of urotensin II in spontaneously hypertensive rats |
| Q46711545 | Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages |
| Q36581189 | Human urotensin II as a link between hypertension and coronary artery disease |
| Q43229377 | Human urotensin II in internal mammary and radial arteries of patients undergoing coronary surgery. |
| Q40122555 | Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease. |
| Q28140469 | Human urotensin II mediates vasoconstriction via an increase in inositol phosphates |
| Q80908840 | Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells |
| Q43927991 | Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists |
| Q43633744 | Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase |
| Q47855077 | Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats |
| Q43264553 | Human urotensin-II is a potent spasmogen of primate airway smooth muscle |
| Q41859635 | Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries |
| Q79732901 | Human urotensin-II potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells: comparison with other vasoactive agents and hydrogen peroxide |
| Q34204725 | Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease |
| Q81485154 | Identification and characterization of binding sites for human urotensin-II in Sprague-Dawley rat renal medulla using quantitative receptor autoradiography |
| Q35047377 | Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines |
| Q98629482 | Identification and signaling characterization of four urotensin II receptor subtypes in the western clawed frog, Xenopus tropicalis |
| Q24299776 | Identification of a novel human eicosanoid receptor coupled to G(i/o) |
| Q28199576 | Identification of four novel human G protein-coupled receptors expressed in the brain |
| Q28215417 | Identification of neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8 |
| Q33495455 | Identification of new agonists of urotensin-II from a cyclic peptide library |
| Q98194098 | Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice |
| Q46719788 | Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor |
| Q86423216 | Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor |
| Q46019919 | Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor. |
| Q28208515 | Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain |
| Q56987894 | Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: Relevance to function |
| Q53535678 | Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues. |
| Q34546327 | Impact of gene/genome duplications on the evolution of the urotensin II and somatostatin families. |
| Q35098581 | In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803) |
| Q48188894 | In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands |
| Q48628455 | Increased circulating concentrations of bioactive PTH 1-84 in patients with heart failure |
| Q36959222 | Increased circulating urotensin II in cirrhosis: potential implications in liver disease. |
| Q28276676 | Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta |
| Q37582059 | Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinoma |
| Q47742415 | Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1. |
| Q79711904 | Increased expression of urotensin II-related peptide and its receptor in kidney with hypertension or renal failure |
| Q60713407 | Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure |
| Q45917329 | Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia. |
| Q46703588 | Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes |
| Q78554340 | Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension |
| Q57771749 | Indole-2-carboxamide Derivatives as Potent Urotensin-II Receptor (UT) Antagonists |
| Q53246009 | Influence of Ca2+ and pH on the folding of the prourotensin II precursor. |
| Q52592152 | Inhibition of A-Type K+ Channels by Urotensin-II Induces Sensory Neuronal Hyperexcitability Through the PKCα-ERK Pathway. |
| Q40405628 | Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle |
| Q47982428 | Insight into the role of urotensin II-related peptide tyrosine residue in UT activation |
| Q99565577 | Insights into the Molecular Determinants Involved in Urocontrin and Urocontrin A Action |
| Q28254485 | International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function |
| Q47938344 | Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents |
| Q40509065 | Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization. |
| Q45209611 | Involvement of cyclooxygenase-dependent pathway in contraction of isolated ileum by urotensin II. |
| Q46451358 | Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts |
| Q44035248 | Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats |
| Q24672927 | Is urotensin-II the new endothelin? |
| Q42816763 | Isochromanone-based urotensin-II receptor agonists |
| Q42280581 | Kidney is in trouble with mediators |
| Q58855675 | Lead Optimization of P5U and Urantide: Discovery of Novel Potent Ligands at the Urotensin-II Receptor |
| Q36838222 | Liberation of urotensin II from the teleost urophysis: an historical overview. |
| Q36894876 | Ligand screening system using fusion proteins of G protein-coupled receptors with G protein alpha subunits |
| Q48675996 | Localization of the urotensin II receptor in the rat central nervous system |
| Q74314813 | Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma |
| Q40726820 | Lycopene Inhibits Urotensin-II-Induced Cardiomyocyte Hypertrophy in Neonatal Rat Cardiomyocytes. |
| Q46126382 | Magnolol depresses urotensin-II-induced cell proliferation in rat cardiac fibroblasts |
| Q28140838 | Mammalian PSP24s (alpha and beta isoforms) are not responsive to lysophosphatidic acid in mammalian expression systems |
| Q37888016 | Management of the no-reflow phenomenon |
| Q44859341 | Mechanism of human urotensin II-induced contraction in rat aorta |
| Q36246723 | Metallacyclopeptides: artificial analogues of naturally occurring peptides |
| Q92020568 | Microinjection of urotensin II into the pedunculopontine tegmentum leads to an increase in the consumption of sweet tastants |
| Q94570858 | Microinjection of urotensin II into the rostral ventrolateral medulla increases sympathetic vasomotor tone via the GPR14/ERK pathway in rats |
| Q40735770 | Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey |
| Q33242327 | Molecular characterization and expression of urotensin II and its receptor in the flounder (Platichthys flesus): a hormone system supporting body fluid homeostasis in euryhaline fish. |
| Q35150904 | Molecular evolution of GPCRs: Somatostatin/urotensin II receptors |
| Q33354088 | Molecular subsets in the gene expression signatures of scleroderma skin |
| Q28574132 | Murine and rat cavernosal responses to endothelin-1 and urotensin-II Vasoactive Peptide Symposium |
| Q28281803 | Mutational analysis of the conserved Asp2.50 and ERY motif reveals signaling bias of the urotensin II receptor |
| Q81924199 | N-alkyl-5H-pyrido[4,3-b]indol-1-amines and derivatives as novel urotensin-II receptor antagonists |
| Q39433122 | NADPH Oxidases, Angiogenesis, and Peripheral Artery Disease. |
| Q93341335 | Natural and synthetic peptides in the cardiovascular diseases: An update on diagnostic and therapeutic potentials |
| Q88711774 | Neurohormonal Blockade in Heart Failure |
| Q82274536 | Neurokinin B and urotensin II levels in pre-eclampsia |
| Q37135968 | Neuropeptide interactions and REM sleep: a role for Urotensin II? |
| Q33922451 | Neuropeptides--an overview. |
| Q39853266 | New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide |
| Q44114224 | New insight into the binding mode of peptides at urotensin-II receptor by Trp-constrained analogues of P5U and urantide |
| Q37135979 | New insight into the molecular evolution of the somatostatin family. |
| Q36467321 | New strategies in drug discovery |
| Q42284302 | No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. |
| Q38077760 | No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives. |
| Q36836447 | Nonclassic endogenous novel [corrected] regulators of angiogenesis |
| Q37006055 | Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships |
| Q43280739 | Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits |
| Q36875931 | Nonpeptidic ligands for peptide-activated G protein-coupled receptors. |
| Q40430686 | Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. |
| Q46450248 | Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial. |
| Q34837608 | Novel G-protein-coupled receptor genes expressed in the brain: continued discovery of important therapeutic targets |
| Q42798863 | Novel and potent small-molecule urotensin II receptor agonists |
| Q28202637 | Novel human G-protein-coupled receptors |
| Q92728452 | Novel insights into the role of urotensin II in cardiovascular disease |
| Q37990618 | Novel pathways and therapies in experimental diabetic atherosclerosis |
| Q38371858 | Occurrence of two distinct urotensin II-related peptides in zebrafish provides new insight into the evolutionary history of the urotensin II gene family |
| Q37641575 | Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2 |
| Q43009106 | Optimization of isochromanone based urotensin II receptor agonists |
| Q34442018 | Orphan G protein-coupled receptors in the CNS. |
| Q35794985 | Orphan G protein-coupled receptors: targets for new therapeutic interventions |
| Q34175467 | Orphan G-protein-coupled receptors and natural ligand discovery |
| Q80806008 | Orphan seven transmembrane receptor screening |
| Q24674639 | Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1 |
| Q82253817 | Osteopontin is involved in urotensin II-induced migration of rat aortic adventitial fibroblasts |
| Q36065156 | Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. |
| Q57637536 | Oxidative parameters, oxidative DNA damage, and urotensin-II in schizoaffective disorder patients |
| Q49281473 | Oxidative/antioxidative status, lymphocyte DNA damage, and urotensin-2 receptor level in patients with migraine attacks. |
| Q37422701 | PPAR-gamma expression in animals subjected to volume overload and chronic Urotensin II administration |
| Q39967100 | Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues |
| Q39236752 | Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension. |
| Q45922685 | Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects. |
| Q43263666 | Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist |
| Q28261953 | Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System |
| Q46953321 | Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment |
| Q41981084 | Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain. |
| Q42976039 | Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites |
| Q36328664 | Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study |
| Q80209644 | Plasma concentration of urotensin II is raised in hypertension |
| Q28216724 | Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure |
| Q51641972 | Plasma urotensin II as a marker for severity of rheumatic valve disease. |
| Q74811631 | Plasma urotensin II in heart failure |
| Q48434734 | Plasma urotensin in human systolic heart failure |
| Q35873683 | Postgenomic characterization of G-protein-coupled receptors |
| Q46559124 | Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles |
| Q31833949 | Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries |
| Q35128456 | Potential Clinical Implications of the Urotensin II Receptor Antagonists |
| Q46248274 | Predicted ligands for the human urotensin-II G protein-coupled receptor with some experimental validation |
| Q42397196 | Prediction of the three-dimensional structure for the rat urotensin II receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations |
| Q43625466 | Pressor and renal regional hemodynamic effects of urotensin II in neonatal pigs. |
| Q46053034 | Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations |
| Q40606119 | Production and characterization of monoclonal antibodies against the vasoconstrictive peptide human urotensin-II. |
| Q46847093 | Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells |
| Q50600080 | Prolonged RXFP1 and RXFP2 signaling can be explained by poor internalization and a lack of beta-arrestin recruitment. |
| Q84003381 | Protective effect of urantide against ischemia-reperfusion injury via protein kinase C and phosphtidylinositol 3'-kinase - Akt pathway |
| Q34001118 | Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis |
| Q40381964 | Purification and characterization of bioactive peptides RYamide and CCHamide in the kuruma shrimp Marsupenaeus japonicus |
| Q47862440 | Purification and characterization of rat des-Gln14-Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor |
| Q39084425 | RGS2 regulates urotensin II-induced intracellular Ca2+ elevation and contraction in glomerular mesangial cells. |
| Q48095541 | Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype |
| Q37015817 | Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides |
| Q35545386 | Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation |
| Q37554198 | Renal Urotensin II System Plays Roles in the Regulation of Blood Pressure in Dahl Salt-Resistant Rat. |
| Q28249171 | Renal and vascular actions of urotensin II |
| Q46882457 | Renal effects of human urotensin-II in rats with experimental congestive heart failure |
| Q35025464 | Renal impairment, hypertension and plasma urotensin II. |
| Q59666960 | Required reading |
| Q34154714 | Retracted: Endogenous Urotensin II Selectively Modulates Erectile Function through eNOS |
| Q37149912 | Ribosomal synthesis of nonstandard peptides |
| Q33323634 | Ribosomal synthesis of peptidase-resistant peptides closed by a nonreducible inter-side-chain bond |
| Q44851444 | Role of ERK and Rho kinase pathways in central pressor action of urotensin II. |
| Q28572971 | Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction |
| Q40950590 | Role of UTS2 gene in the genetic susceptibility to atrial fibrillation in the Chinese population |
| Q46754132 | Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats |
| Q36902874 | Role of urotensin II and its receptor in health and disease |
| Q28182651 | Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects |
| Q37209169 | Role of urotensin II in atherosclerotic cardiovascular diseases |
| Q37737495 | Role of urotensin II in health and disease |
| Q74531870 | Role of urotensin II in patients on dialysis |
| Q35914491 | Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor |
| Q39190431 | Role of urotensin II in advanced glycation end product-induced extracellular matrix synthesis in rat proximal tubular epithelial cells |
| Q28156450 | Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities |
| Q33287364 | Seasonal changes in peptide, receptor and ion channel mRNA expression in the caudal neurosecretory system of the European flounder (Platichthys flesus). |
| Q48372089 | Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma. |
| Q30658328 | Singular contributions of fish neuroendocrinology to mammalian regulatory peptide research |
| Q33345385 | Skin vasodilator effect of exogenous urotensin-II in hypertensives not exposed to antihypertensive medication |
| Q44452553 | Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II. |
| Q34278176 | Somatostatins and their receptors in fish |
| Q73568813 | Specific expression of the urotensin II gene in sacral motoneurons of developing rat spinal cord |
| Q38533390 | State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells |
| Q40083973 | Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11). |
| Q39848088 | Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor |
| Q57951237 | Structure-activity relationship study on human urotensin II |
| Q45100855 | Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. |
| Q44564935 | Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction |
| Q28252914 | Structure-activity relationships of urotensin II and URP |
| Q43660489 | Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells |
| Q43810240 | Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation |
| Q90902969 | Synthesis and SAR of 5-aryl-furan-2-carboxamide derivatives as potent urotensin-II receptor antagonists |
| Q57771776 | Synthesis and SAR of thieno[3,2- b ]pyridinyl urea derivatives as urotensin-II receptor antagonists |
| Q34525952 | Target validation of G-protein coupled receptors |
| Q46181459 | Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet |
| Q90529594 | Targeting of G-protein coupled receptors in sepsis |
| Q35737651 | Techniques: Cardiovascular pharmacology and drug discovery in the 21st century |
| Q30486707 | The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors |
| Q33599835 | The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features |
| Q83594973 | The HIF1 target gene NOX2 promotes angiogenesis through urotensin-II |
| Q52655219 | The Protective Effect of Total Flavones from Rhododendron simsii Planch. on Myocardial Ischemia/Reperfusion Injury and Its Underlying Mechanism. |
| Q40612721 | The Relation Between No-Reflow Phenomenon and Complete Blood Count Parameters |
| Q93949482 | The Sixth International Conference on Endothelin. October 1999, Montreal, Canada |
| Q36973674 | The Urotensin II System and Carotid Atherosclerosis: A Role in Vascular Calcification |
| Q45779881 | The differential extraction and immunoluminometric assay of Urotensin II and Urotensin-related peptide in heart failure |
| Q42283626 | The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans. |
| Q28241656 | The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma |
| Q34292565 | The identification of ligands at orphan G-protein coupled receptors |
| Q35640192 | The impact of the completed human genome sequence on the development of novel therapeutics for human disease |
| Q83187966 | The in vivo effects of human urotensin II in the rabbit and rat pulmonary circulation: effects of experimental pulmonary hypertension |
| Q84444107 | The interaction between human urotensin II and vasodilator agents in human internal mammary artery with possible clinical implications |
| Q54565478 | The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. |
| Q28299929 | The multifunctional fish gill: dominant site of gas exchange, osmoregulation, acid-base regulation, and excretion of nitrogenous waste |
| Q40644520 | The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors |
| Q35538538 | The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy |
| Q35100902 | The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems |
| Q73143605 | The physiological response to cardiovascular 'orphan' G protein-coupled receptor agonists |
| Q54691256 | The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1/2 and PI3K signaling pathways. |
| Q93337984 | The relationship between urotensin II and insulin resistance in women with gestational diabetes mellitus |
| Q80345675 | The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease |
| Q37499240 | The renin-angiotensin system, adrenomedullins and urotensin II in the kidney: possible renoprotection via the kidney peptide systems. |
| Q39093111 | The role of neuropeptides in adverse myocardial remodeling and heart failure. |
| Q53224729 | The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer. |
| Q24675590 | The role of urotensin II in cardiovascular and renal physiology and diseases |
| Q36870291 | The role of urotensin II in the metabolic syndrome |
| Q50043875 | The role of urotensin-II and its receptors in sepsis-induced lung injury under diabetic conditions. |
| Q39060095 | The role of water-soluble meconium subfraction and lipid-soluble meconium subfraction on the superior mesenteric artery vasoconstriction in chick embryos |
| Q89704968 | The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure |
| Q28211211 | The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat |
| Q46788574 | The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats |
| Q42213734 | The vasoactive peptide urotensin II stimulates spontaneous release from frog motor nerve terminals |
| Q43146165 | The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation |
| Q38196857 | Therapeutic implications of peptide interactions with G-protein-coupled receptors in diabetic vasculopathy |
| Q36760529 | Therapeutic potential of blockade of the urotensin II system in systemic hypertension |
| Q93214358 | Therapeutic potential of urotensin II receptor antagonist in chronic kidney disease and associated comorbidities |
| Q37082781 | Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors? |
| Q46647178 | Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model |
| Q48887995 | Time-course effects of centrally administered native urotensin-II on motor and cardioventilatory activity in trout |
| Q51970096 | Transcriptional profiling of the megabladder mouse: a unique model of bladder dysmorphogenesis. |
| Q35683782 | Translational medicine in fish-derived peptides: from fish endocrinology to human physiology and diseases |
| Q54680530 | UII and UT in grouper: cloning and effects on the transcription of hormones related to growth control. |
| Q73746130 | UROTENSIN II: BETTER THAN SOMATOSTATIN FOR PORTAL HYPERTENSION? |
| Q90304179 | UTS2B Defines a Novel Enteroendocrine Cell Population and Regulates GLP-1 Secretion Through SSTR5 in Male Mice |
| Q87926804 | UTS2R gene polymorphisms are associated with fatty acid composition in Japanese beef cattle |
| Q26801739 | Unravelling osteoarthritis-related synovial fibrosis: a step closer to solving joint stiffness |
| Q38928104 | Up-regulation of urotensin II and its receptor contributes to human hepatocellular carcinoma growth via activation of the PKC, ERK1/2, and p38 MAPK signaling pathways. |
| Q41767436 | Update on the urotensinergic system: new trends in receptor localization, activation, and drug design |
| Q54427703 | Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia. |
| Q90373725 | Urantide Improves Cardiac Function, Modulates Systemic Cytokine Response and Increases Survival in a Murine Model of Endotoxic Shock |
| Q83593149 | Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats |
| Q54414485 | Urantide conformation and interaction with the urotensin-II receptor. |
| Q51823933 | Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. |
| Q41819007 | Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta |
| Q51762676 | Urocontrin, a novel UT receptor ligand with a unique pharmacological profile. |
| Q35914470 | Urocortins as cardiovascular peptides. |
| Q36176966 | Urolinin: The First Linear Peptidic Urotensin-II Receptor Agonist |
| Q46625776 | Urotensin 2 in Kawasaki disease pathogenesis. |
| Q39983107 | Urotensin I-CRF-Urocortins: a mermaid's tail. |
| Q87173105 | Urotensin II (U-II), a novel cyclic peptide, possibly associated with the pathophysiology of osteoarthritis |
| Q42578695 | Urotensin II Exerts Pressor Effects By Stimulating Renin And Aldosterone Synthase Gene Expression. |
| Q93016390 | Urotensin II Induces Mice Skeletal Muscle Atrophy Associated with Enhanced Autophagy and Inhibited Irisin Precursor (Fibronectin Type III Domain Containing 5) Expression in Chronic Renal Failure |
| Q35813861 | Urotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S Pathway |
| Q28573864 | Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol |
| Q46433577 | Urotensin II acts as a modulator of mesopontine cholinergic neurons |
| Q28190334 | Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions |
| Q62026465 | Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling |
| Q34192302 | Urotensin II alters vascular reactivity in animals subjected to volume overload |
| Q36969386 | Urotensin II and atherosclerosis. |
| Q46845258 | Urotensin II and cardiomyopathy in end-stage renal disease. |
| Q35914500 | Urotensin II and cardiovascular diseases |
| Q28576132 | Urotensin II and renal function in the rat |
| Q38063802 | Urotensin II and the kidney |
| Q28571161 | Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury |
| Q46741797 | Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5. |
| Q44654245 | Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a “vasoconstrictor” with a unique hemodynamic profile |
| Q36424203 | Urotensin II contributes to the formation of lung adenocarcinoma inflammatory microenvironment through the NF-κB pathway in tumor-bearing nude mice |
| Q83534407 | Urotensin II differentially regulates macrophage and hepatic cholesterol homeostasis |
| Q41834073 | Urotensin II evokes potent vasoconstriction in humans in vivo |
| Q39112463 | Urotensin II exerts antiapoptotic effect on NRK-52E cells through prostacyclin-mediated peroxisome proliferator-activated receptor alpha and Akt activation |
| Q84615623 | Urotensin II immunoreactivity in the human circulation: evidence for widespread tissue release |
| Q37344439 | Urotensin II in cardiovascular regulation |
| Q33378279 | Urotensin II in chronic liver disease: in vivo effect on vascular tone |
| Q36384743 | Urotensin II in invertebrates: from structure to function in Aplysia californica |
| Q81793693 | Urotensin II in patients with chronic heart failure |
| Q35914504 | Urotensin II in the cardiovascular system. |
| Q64237884 | Urotensin II in the development and progression of chronic kidney disease following ⅚ nephrectomy in the rat |
| Q38956381 | Urotensin II increases foam cell formation by repressing ABCA1 expression through the ERK/NF-κB pathway in THP-1 macrophages |
| Q43798438 | Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats |
| Q35108921 | Urotensin II induces interleukin 8 expression in human umbilical vein endothelial cells |
| Q54705415 | Urotensin II induces migration of endothelial progenitor cells via activation of the RhoA/Rho kinase pathway. |
| Q28583409 | Urotensin II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta |
| Q57779384 | Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3β signaling pathway |
| Q33991646 | Urotensin II inhibited the proliferation of cardiac side population cells in mice during pressure overload by JNK-LRP6 signalling |
| Q51299154 | Urotensin II inhibitor eases neuropathic pain by suppressing the JNK/NF-κB pathway. |
| Q48627768 | Urotensin II inhibits carotid sinus baroreflex in anesthetized male rats |
| Q34275989 | Urotensin II inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating ATF expression and via the ERK and Akt pathway |
| Q35014906 | Urotensin II inhibits skeletal muscle glucose transport signaling pathways via the NADPH oxidase pathway |
| Q28235675 | Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes |
| Q44463826 | Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney |
| Q38359653 | Urotensin II is an autocrine/paracrine growth factor for aortic adventitia of rat. |
| Q40655118 | Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. |
| Q58949058 | Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease |
| Q58949856 | Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease |
| Q48455632 | Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans |
| Q42833174 | Urotensin II is raised in children with congenital heart disease |
| Q30807054 | Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). |
| Q44354767 | Urotensin II levels are an important marker for the severity of portal hypertension in children |
| Q51840588 | Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines. |
| Q43268409 | Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats |
| Q28584202 | Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons |
| Q50253358 | Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK. |
| Q47275813 | Urotensin II promotes aldosterone expression in rat aortic adventitial fibroblasts |
| Q35152923 | Urotensin II promotes atherosclerosis in cholesterol-fed rabbits |
| Q44942872 | Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases |
| Q84172785 | Urotensin II protects ischemic reperfusion injury of hearts through ROS and antioxidant pathway |
| Q45732640 | Urotensin II receptor (UTR) exists in hyaline chondrocytes: a study of peripheral distribution of UTR in the African clawed frog, Xenopus laevis |
| Q42974286 | Urotensin II receptor and acetylcholine release from mouse cervical spinal cord nerve terminals |
| Q50796108 | Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes. |
| Q42876530 | Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats. |
| Q92028606 | Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats |
| Q43288560 | Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype |
| Q53750044 | Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. |
| Q43246636 | Urotensin II stimulates high frequency-induced ANP secretion via PLC-PI 3K-PKC pathway |
| Q40470611 | Urotensin II stimulates plasma extravasation in mice via UT receptor activation. |
| Q53529593 | Urotensin II upregulates migration and cytokine gene expression in leukocytes of the African clawed frog, Xenopus laevis. |
| Q35914486 | Urotensin II, a novel peptide in central and peripheral cardiovascular control |
| Q28287953 | Urotensin II, from fish to human |
| Q91076523 | Urotensin II, urotensin-related peptide, and their receptor in aortic valve stenosis |
| Q48877778 | Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat. |
| Q78700092 | Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling |
| Q46899967 | Urotensin II-induced collagen synthesis in cultured smooth muscle cells from rat aortic media and a possible involvement of transforming growth factor-β1/Smad2/3 signaling pathway |
| Q45947381 | Urotensin II-induced endothelin-1 expression and cell proliferation via epidermal growth factor receptor transactivation in rat aortic smooth muscle cells. |
| Q46617923 | Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats |
| Q37063375 | Urotensin II-induced insulin resistance is mediated by NADPH oxidase-derived reactive oxygen species in HepG2 cells |
| Q34139078 | Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells |
| Q35914509 | Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain |
| Q57718582 | Urotensin II: A Novel Target in Human Corpus Cavernosum |
| Q37085432 | Urotensin II: a cardiovascular and renal update |
| Q74531840 | Urotensin II: a new mediator in cardiopulmonary regulation? |
| Q37139056 | Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease |
| Q40166897 | Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension |
| Q90849664 | Urotensin II: an inflammatory cytokine |
| Q28250440 | Urotensin II: ancient hormone with new functions in vertebrate body fluid regulation |
| Q48761612 | Urotensin II: evidence for cardiac, hepatic and renal production |
| Q33846563 | Urotensin II: fish neuropeptide catches orphan receptor |
| Q80210305 | Urotensin II: from osmoregulation in fish to cardiovascular regulation in man |
| Q36121966 | Urotensin II: its function in health and its role in disease. |
| Q37148984 | Urotensin II: lessons from comparative studies for general endocrinology. |
| Q35756527 | Urotensin II: the old kid in town. |
| Q60713386 | Urotensin Peptides |
| Q85276064 | Urotensin inhibition with palosuran could be a promising alternative in pulmonary arterial hypertension |
| Q57793656 | Urotensin receptors as a new target for CLP induced septic lung injury in mice |
| Q54534462 | Urotensin upregulates transforming growth factor-β1 expression of asthma airway through ERK-dependent pathway. |
| Q54643074 | Urotensin-2 promotes collagen synthesis via ERK1/2-dependent and ERK1/2-independent TGF-β1 in neonatal cardiac fibroblasts. |
| Q50298297 | Urotensin-2 receptor binds urotensin-2 and 2B |
| Q84220611 | Urotensin-II 143 G/A polymorphism is not associated with the risk of preeclampsia in Korean women |
| Q38093584 | Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures |
| Q60446259 | Urotensin-II Signaling Mechanism in Rat Coronary Artery |
| Q45121672 | Urotensin-II activates L-arginine/nitric oxide pathway in isolated rat aortic adventitia |
| Q36995672 | Urotensin-II and cardiovascular remodeling |
| Q35779239 | Urotensin-II and the cardiovascular system--the importance of developing modulators |
| Q37719814 | Urotensin-II as an angiogenic factor |
| Q53615834 | Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. |
| Q43266046 | Urotensin-II contributes to pulmonary vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary to meconium aspiration syndrome |
| Q33229777 | Urotensin-II expression in the mouse spinal cord |
| Q64940598 | Urotensin-II gene rs228648 polymorphism associated with the risk of diabetes mellitus. |
| Q80677674 | Urotensin-II immunoreactivity in children with chronic glomerulonephritis |
| Q36357772 | Urotensin-II induces ear flushing in rats |
| Q81594348 | Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig |
| Q82728342 | Urotensin-II levels in acute coronary syndromes |
| Q45189333 | Urotensin-II levels in children with minimal change nephrotic syndrome |
| Q41872921 | Urotensin-II promotes vascular smooth muscle cell proliferation through store-operated calcium entry and EGFR transactivation |
| Q46523374 | Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides. |
| Q28572342 | Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease |
| Q39039151 | Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans. |
| Q35821444 | Urotensin-II receptor peptide agonists |
| Q35221658 | Urotensin-II receptor stimulation of cardiac L-type Ca2+ channels requires the βγ subunits of Gi/o-protein and phosphatidylinositol 3-kinase-dependent protein kinase C β1 isoform. |
| Q44208844 | Urotensin-II regulates intracellular calcium in dissociated rat spinal cord neurons |
| Q35082405 | Urotensin-II system in genetic control of blood pressure and renal function |
| Q47365499 | Urotensin-II, a neuropeptide ligand for GPR14, induces c-fos in the rat brain |
| Q44790676 | Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro. |
| Q28566263 | Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators |
| Q54351967 | Urotensin-II-stimulated expression of pro-angiogenic factors in human vascular endothelial cells. |
| Q42418210 | Urotensin-II: More Than a Mediator for Kidney |
| Q76383739 | Urotensin-II: a novel systemic hypertensive factor in the cat |
| Q61443428 | Urotensin-related gene transcripts mark developmental emergence of the male forebrain vocal control system in songbirds |
| Q35895186 | Urotensin-ⅡReceptor Antagonist SB-710411 Protects Rat Heart against Ischemia-Reperfusion Injury via RhoA/ROCK Pathway |
| Q47587344 | Urotensinergic system genes in experimental subarachnoid hemorrhage. |
| Q33705948 | Urotensin‐II receptor antagonism does not improve renal haemodynamics or function in rats with endotoxin‐induced acute kidney injury |
| Q46700830 | Vascular contractile effect of urotensin II in young and aged rats: influence of aging and contribution of endothelial nitric oxide |
| Q35536658 | Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries |
| Q74162696 | Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries |
| Q53427983 | [Changes in serum chromogranin A and urotensin II levels in children with chronic heart failure]. |
| Q28568929 | [Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes |
| Q80347519 | [What progress can be expected in the management of hypertension? Forecast from 1974 to 2034] |